ADMA
Adma Biologics Inc
Adma Biologics Inc
$ADMA reports growth in revenue for Q1 2023 and expects increased profitability soon
ADMA Biologics Inc. reports positive Q1 2023 financial results with revenue growth, reflecting increased sales of its immunoglobulin products. CEO Adam Grossman has expressed confidence in the company's outlook and expects adjusted EBITDA growth of $210 million for 2023. Further growth initiatives are expected to set the foundation for a highly profitable growth cycle. The company's gross margin has increased, and operating efficiency has improved, making ADMA a promising investment option.
4mo ago
$ADMAAdma Biologics Inc
$ADMA reports record revenue growth, opportunities for future earnings, and expanded product portfolio.
ADMA Biologics reports Q4 revenue of $50.2M due to increased sales of ASCENIV, leading to record number of patients treated and strong market share gains. The focus on immune-deficient patient segment could lead to potential revenue and earnings growth beyond prior guidance. Positive EBITDA is expected in H2 2023. The company aims to drive profitability ahead, and expects favorable product mix to continue. Expansion of product portfolio is also planned.
6mo ago
$ADMA